NCT06806852 2026-03-18
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Boehringer Ingelheim
Phase 1 Recruiting
Clinical Trials
61 trialsNCT04590963 2026-03-13
INTERLINK-1
AstraZeneca
Phase 3 Active not recruiting
NCT04892173 2026-03-13
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Johnson & Johnson Enterprise Innovation Inc.
Phase 3 Recruiting
NCT07435311 2026-02-27
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
Phase 1 Completed
NCT07435324 2026-02-27
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
Phase 3 Active not recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT05355701 2026-02-03
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT05249426 2026-01-21
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06194656 2026-01-16
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Shanghai Institute Of Biological Products
Phase 2 Recruiting
NCT07216105 2025-12-17
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT04428151 2025-12-04
LEAP-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT05226871 2025-11-25
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
Phase 2 Active not recruiting
NCT05271604 2025-09-26
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BioAtla, Inc.
Phase 2 Completed
NCT05061420 2025-09-22
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Sanofi
Phase 2 Terminated
NCT07059221 2025-07-22
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05910827 2025-06-22
Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Phase 1/2 Recruiting
NCT04616196 2025-06-08
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Nektar Therapeutics
Phase 1/2 Completed
NCT06943820 2025-06-03
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
Phase 1/2 Recruiting
NCT06064877 2025-04-13
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT02741570 2023-09-21
CheckMate 651
Bristol-Myers Squibb
Phase 3 Completed
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT02499120 2023-09-08
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Pfizer
Phase 2 Completed
NCT02643550 2023-05-12
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Innate Pharma
Phase 1/2 Completed
NCT03254927 2023-04-03
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Celldex Therapeutics
Phase 2 Terminated
NCT05751512 2023-03-02
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Shanghai Miracogen Inc.
Phase 3 Unknown
NCT02627274 2022-11-22
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Hoffmann-La Roche
Phase 1 Completed
NCT02105636 2022-10-05
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Bristol-Myers Squibb
Phase 3 Completed
NCT04065555 2022-07-29
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
Presage Biosciences
Phase EARLY_PHASE1 Completed
NCT01332266 2022-01-03
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Eisai Inc.
Phase 1/2 Completed
NCT02052960 2021-11-02
RESGEX
Glycotope GmbH
Phase 2 Completed
NCT03349710 2021-08-09
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT03552406 2021-05-06
Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
ISU Abxis Co., Ltd.
Phase 1 Unknown
NCT02817113 2021-04-30
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
Orient Europharma Co., Ltd.
Phase 1 Terminated
NCT03342352 2019-12-20
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
Phase 3 Withdrawn
NCT02124850 2019-10-25
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Celgene
Phase 1 Terminated
NCT01063075 2019-09-26
A Study in Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT03386838 2019-04-18
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT02555644 2019-02-15
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated
NCT02350712 2018-09-11
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00617734 2018-04-17
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
Eli Lilly and Company
Phase 2 Completed
NCT02110082 2017-04-19
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00927147 2017-01-31
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
Boneca Corporation
Phase 1/2 Terminated
NCT01577173 2016-11-02
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Genentech, Inc.
Phase 2 Completed
NCT01046266 2016-09-14
A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma
Hoffmann-La Roche
Phase 1 Completed